Alternative splicing of the proteolipid protein 1 gene (PLP1) produces two forms, PLP1 and DM20, due to alternative use of 5 ′ splice sites with the same acceptor site in intron 3. The PLP1 form predominates in central nervous system RNA. Mutations that reduce the ratio of PLP1 to DM20, whether mutant or normal protein is formed, result in the X-linked leukodystrophy Pelizaeus-Merzbacher disease (PMD). We investigated the ability of sequences throughout PLP1 intron 3 to regulate alternative splicing using a splicing minigene construct transfected into the oligodendrocyte cell line, Oli-neu. Our data reveal that the alternative splice of PLP1 is regulated by a long-distance interaction between two highly conserved elements that are separated by 581 bases within the 1071-base intron 3. Further, our data suggest that a base-pairing secondary structure forms between these two elements, and we demonstrate that mutations of either element designed to destabilize the secondary structure decreased the PLP1/DM20 ratio, while swap mutations designed to restore the structure brought the PLP1/DM20 ratio to near normal levels. Sequence analysis of intron 3 in families with clinical symptoms of PMD who did not have coding-region mutations revealed mutations that segregated with disease in three families. We showed that these patient mutations, which potentially destabilize the secondary structure, also reduced the PLP1/ DM20 ratio. This is the first report of patient mutations causing disease by disruption of a long-distance intronic interaction controlling alternative splicing. This finding has important implications for molecular diagnostics of PMD.
INTRODUCTION
One of the major challenges facing molecular diagnostics professionals today is determining whether a particular DNA variant is pathogenic. When the variant is in a coding region and results in an amino acid change, or it is in a splice donor or acceptor site, there are computer algorithms to help predict pathogenicity (1 -6) . However, when the variants are in other DNA regions, it can be difficult to predict the outcomes for patients (7 -9) , and the main avenue currently available is to determine a potential mechanism for the variant of unknown significance and design an assay to test it. For example, variants in transcriptional enhancer regulatory regions, those in potential alternative splicing enhancer or silencer regions and those within introns can be tested in transfection experiments and transgenic animals, and by protein factor binding assays to help predict pathogenicity. Although interesting disease mechanisms have been identified for variants in introns, including activation of † cryptic splice sites and interruption of secondary structure at splice sites (7, 8, 10) , the current practice in many molecular diagnostics laboratories is to sequence only coding, and splice donor and acceptor sequences, and sometimes the promoter regions of genes.
In the 13 years that our Molecular Diagnostics Laboratory at Nemours/Alfred I. duPont Hospital for Children has been testing for mutations of the proteolipid protein 1 gene (PLP1) in the X-linked leukodystrophy Pelizaeus-Merzbacher disease (PMD), many patients have tested negative, in large part due to difficulties inherent in clinical diagnosis of PMD because of the wide disability spectrum and the overlap of symptoms with other leukodystrophies. The disability spectrum in PMD ranges from patients with mild developmental delay who are able to walk and speak into their teen years to patients with severe developmental delay who never walk and never develop speech. Results of magnetic resonance imaging (MRI) testing of PMD patients show a diffuse pattern of hypomyelination and clinical signs include nystagmus, hypotonia progressing to spasticity, ataxia, titubation, tremors, athetotic movements and differing degrees of cognitive impairment (11, 12) . These MRI results and clinical signs are shared by patients with Pelizaeus-Merzbacher-like disease (MIM#608803) caused by autosomal recessive mutations of the gap junction protein, gamma 2 gene (GJC2), and they overlap with the MRI results and clinical signs of patients who have other leukodystrophies, such as hypomyelination with congenital cataract caused by mutations of the family with sequence similarity 126, member A gene (FAM126A, MIM# 610531), 4H syndrome caused by mutations of the polymerase (RNA) III (DNA-directed) polypeptide A and polypeptide B genes (POLR3A, MIM#614258; POLR3B, MIM#614366), and Allan-Herndon-Dudley syndrome caused by mutations of the solute carrier family 16, member 2 gene (SLC16A2, also called MCT8, MIM#300095). Testing for other leukodystrophies may be considered when molecular diagnostic testing for PMD is negative (11) . However, because the families of some patients who test negative for PMD show strong X-linked recessive inheritance and we and others have shown that the alternative splice of PLP1 is important for normal function (13) (14) (15) (16) , we postulated that PMD-causing mutations might be found in regulatory regions for alternative splicing of PLP1 that were not being sequenced by our molecular diagnostics laboratory.
The normal splicing pattern of the PLP1 gene product includes two alternatively spliced transcripts, PLP1 and DM20, due to use of two alternative splice donor sites for exon 3A and 3B joining the same acceptor site for exon 4 (Fig. 1A) . The PLP1 transcript, which is the predominant form expressed in myelin-producing oligodendrocytes of the central nervous system (CNS), is 105 bases longer than DM20 and gives rise to a protein that is 35 amino acids larger. The alternatively spliced forms are developmentally regulated, as DM20 is the predominant form prior to onset of myelination, but the PLP1 isoform becomes the predominant form when transcription of the PLP1 dramatically increases during myelination (17, 18) . We and others have described the effects of patient mutations at the PLP1 and DM20 splice donor sites and their common acceptor site, as well as patient mutations within exonic and intronic enhancers of PLP1 alternative splicing (13) (14) (15) (16) (19) (20) (21) . Patient mutations in exonic enhancers were detected in routine sequencing conducted by our diagnostics laboratory. The previously described intronic enhancer was detected because it is close to the splice donor site for the PLP1 form and within the region amplified and sequenced using the primers selected for sequencing exon 3 (13, 14) .
To determine potential mechanisms that could be disrupted by patient mutations in regulatory regions for alternative splicing of PLP1, we extended our splicing analyses to the whole of intron 3, a 1071-base intron. Here, we report that intron 3 has regions throughout its length that affect alternative splicing. A particularly strong regulatory element was identified at 323 to 308 bases upstream of the splice acceptor. We showed that this element participates in a long-distance interaction with another element that is 151-166 bases from the splice donor site of intron 3. Our data suggest that these two elements in the pre-mRNA participate in a double-stranded intra-intronic secondary structure that controls PLP1 alternative splicing. In addition, we report that patients in three families with no coding mutations of PLP1 whose clinical signs were highly suggestive of PMD had mutations in one of these elements. These mutations, which were predicted to destabilize the secondary structure, reduced the PLP1/DM20 ratio. Our data strongly suggest that a secondary structure within intron 3 is important for controlling regulation of the PLP1 alternative splice and that patient mutations can cause PMD by disrupting this structure. We therefore advise molecular diagnostics laboratories to include intron 3 when sequencing PLP1 for PMD diagnostics. This is the first report of patient mutations that cause disease by disrupting a long-distance intronic interaction controlling alternative splicing.
RESULTS
Deletions throughout intron 3 of PLP1 greatly reduced the ratio of PLP1 to DM20 alternatively spliced products PLP1 is subject to alternative splicing, by use of either of two possible donor sites for exon 3 (Fig. 1A) . We postulated that intron 3 of PLP1 might contain sequences important for regulation of the alternative splice and that PMD patient mutations could occur in these regulatory regions for several reasons. Intronic splicing enhancers (ISEs) and silencers (ISSs) are known to regulate alternative splicing of other genes (22) . Also, we and others have identified splice site mutations that affect alternative splicing of PLP1 and cause PMD, some of which do not cause amino acid changes (13, 14, 16, 21) , and we have identified a patient mutation that disrupts an enhancer of PLP1/DM20 alternative splicing (13, 23) . We examined the conservation of sequences in intron 3 because conserved regions can indicate conserved function, such as a binding site for splicing regulatory factors (24) (25) (26) . While intron 3 of PLP1 is 78% identical between mouse and human, the other introns of human PLP1 range from 47 to 64% identity to mouse (alignments not shown), suggesting that sequences in intron 3 may regulate PLP1/DM20 alternative splicing throughout the mammalian lineage.
To determine whether regulatory regions for the PLP1/DM20 alternative splice are limited to the immediate vicinity of the splice site or are located throughout intron 3, we created six overlapping deletions of 210 bp each in the minigene splicing Human Molecular Genetics, 2014, Vol. 23, No. 20 5465 construct (deletions A-F; Fig. 1C ) and tested them by transfection into the Oli-neu cell line. The minigene splicing construct and Oli-neu cell line have been used previously for analysis of PLP1/DM20 splicing (20, 23, (27) (28) (29) , and results from analysis of splicing constructs were comparable with rat primary oligodendrocyte cultures (27) . RT-PCR was performed on the resulting RNA. Removal of any of the 210 bp regions, termed A -F (Fig. 1C) , resulted in a significant reduction in the PLP1/ DM20 ratio (Fig. 1D) . In particular, deletion of the E region, c.454-406_-197, was able to influence the choice of donor splice site from nearly 700 bases downstream, decreasing the PLP1/DM20 ratio to 0.07. Additionally, testing of constructs in which the deletions were filled with a replacement sequence yielded similar results (Fig. 1E) , indicating that the reductions of the PLP1/DM20 ratio were not due to compacting the intron. The data showed that sequences throughout intron 3 had a significant influence on the PLP1/DM20 ratio.
Three patient mutations and other base substitutions in intron 3 reduced the PLP1/DM20 ratio
In parallel to our direct testing of the intron 3 mutant constructs, we conducted a molecular analysis for potential spliceregulatory mutations in intron 3 of PLP1 in candidate families with mild classical PMD and suggested X-linked inheritance but no mutations in coding regions of PLP1 or GJC2 and no duplication of the PLP1 locus. The clinical presentation summary is in Table 1 , and brain MRI is in Supplementary Material, Figure, S1A. In families A and C, we examined the CA microsatellite marker in intron 3 (30) , and PLP1 was implicated as the possible disease-causing gene (data not shown). On further analysis of these families and in family B, we identified sequence variants in intron 3 of PLP1 that were not previously described: family A, c.454-322G.A; family B, c.454-314T.A; family C, c.454-314T.G. In each family, the sequence variant segregated with disease, implicating the variants as the disease-causing mutations (Fig. 2) . To confirm that the mutation c.454-322G.A altered splicing of PLP1 in patient cells, we characterized the PLP1/DM20 ratio in cultured skin fibroblasts from the patient (II.5) in family A. RT-PCR of RNA from patient fibroblasts and a normal fibroblast control demonstrated a reduction of PLP1 message in the fibroblasts from the affected individual II.5 (Supplementary Material, Fig. S1B ). The levels of PLP1 expressed in the cells of the patient were 6 -9% of normal. Skin fibroblasts were not available from patients in families B and C.
The three patient mutations are within the 210-base E region, removal of which reduced the PLP1/DM20 alternative splice ratio (Fig. 1D) . To further narrow down potential sequences A portion of the human PLP1 gene containing the PLP1/DM20 alternative splice was inserted into the pRSVneo plasmid. Primers used to determine the relative levels of PLP1 and DM20 in RT-PCR of mRNA produced from the construct in transfected cells are represented by the short black arrows above (forward primer neo-ex2F) and below (reverse primer neo-ex4R) the diagram boxes. The primers overlap the neo and PLP1 sequences. (C) Diagrams of constructs with 210-base overlapping portions of PLP1 intron 3 either deleted or replaced with 210 bases of unrelated sequence. Letters to the left were used to name the deletion and replacement constructs. (D) Quantification of PLP1/DM20 mRNA in Oli-neu cells transfected with deletion constructs. Standard deviation for normal was +0.00. (E) Quantification of PLP1/DM20 mRNA in Oli-neu cells transfected with replacement constructs. Standard deviation for normal was +0.01. Graphs in (D) and (E) represent the ratio of PLP1 product to the DM20 product normalized to the value for the normal construct (mean of replicates + SD). All constructs were tested in triplicate. In cases where constructs were tested in repeated experiments, the mean of the ratio, standard deviations and t-tests are presented. Mutated constructs that had an expression ratio significantly different from the normal construct, as measured by Student's t-test, are indicated: * * * P , 0.001; * * P , 0.01. Continued that influence alternative splicing in the region surrounding the patient mutations, we introduced a series of seven 10-base deletions into the splicing minigene construct (deletions 1 -7; Fig. 3A ) and tested them by transfection into Oli-neu cells. Deletion 5, which included position c.454-314 where the mutations in families B and C are located, caused a highly significant reduction in the PLP1/DM20 ratio to 0.02 ( Fig. 3B ), similar to that of the deletion of the entire E region, which was 0.07 ( Fig. 1D ). Unexpectedly, deletion 4, which included position c.454-322 where the mutation in family A is located, did not cause reduction of the PLP1/DM20 ratio. However, we noted sequence similarity between bases in regions 3 and 4 ( Fig. 3C) . If the sequence of region 4 must be next to region 5 for splicing to occur, then we may have compensated for the function of the sequence in region 4 by moving the similar sequence in region 3 next to region 5.
To test the hypothesis that sequences in regions 4 and 5 are responsible for maintaining the normal PLP1 isoform levels, a series of mutant constructs was made throughout this region ( Fig. 4A ) and tested by transfection into Oli-neu cells (Fig. 4B ). In designing these constructs, special focus was placed on the c.454-322 and c.454-314 positions, as these were the sites of the patient mutations in our three families. Results indicated that the c.454-322G.A mutation identified in family A reduced the PLP1/DM20 ratio to 0.13 of normal ( Bioinformatics analyses suggest that PLP1/DM20 alternative splicing is dependent on formation of a double-stranded RNA secondary structure between long-distance interacting elements Mutations in introns can cause aberrant alternative splicing by creating or destroying splicing enhancer or silencer motifs that are binding sites for trans-acting factors that influence splice-site selection by interacting with the splicing machinery. For example, a mutation deep within an intron of the fibrinogen beta gene (FGB) creates an ESE that affects alternative splicing by activating the inclusion of a cryptic exon (31) . We performed bioinformatics analyses to identify predicted modifications in potential splicing factor binding sites in regions 4 and 5 due to our introduced mutations and to determine whether the changes could explain our transfection data produced from mutant constructs (Figs 3, 4, and 5, Supplementary Material, Table S1 ). Modification of predicted factor-binding sites did not correlate consistently with the transfection data. For example, the c.454-314T.A mutation in family B and the c.454-314T.G mutation in family C had no effect on predicted ESE sites, but there was a significant reduction in the PLP1/ DM20 ratio when the mutant constructs were tested by transfection. Additionally, two constructs, c.454-309T.C and c.454-308_-307CA.GG, were both predicted to reduce the strength of a SRp40 site, but there was no change in the PLP1/ DM20 ratio for the c.454-309T.C construct, while the c.454-308_-307 CA.GG mutation reduced the PLP1/DM20 ratio to 0.37 of normal. Our data did not suggest a clear connection between the predicted site modifications and our transfection data, so we sought an alternative explanation for how regions 4 and 5 could affect alternative splicing. Alternative splicing can be influenced by pre-mRNA secondary structures that form around splice sites (32) (33) (34) . To search for potential secondary structure involvement in the splicing of intron 3, we analyzed the 1071-base intron 3 of PLP1 by using the mfold program with standard parameters to represent the stability of the most likely secondary structures (35) . The results included 32 potential structures for the intron. The initial delta G values for the first three structures were 2353.4, 2352.9 and 2351.8 kcal/mol. In comparison, another PLP1 intron of similar size, intron 6 with 1127 bases, had delta G-values averaging 2338.3 kcal/mol for the first three structures, indicating that intron 3 structures had a lower free energy and were more likely to be stable than intron 6 structures. In viewing the third structure created by mfold for intron 3, we noted that bases c.454-323 to c.454-308, regions 4 and 5 ( Fig. 3 ) that included the three patient mutations, formed a double-stranded RNA structure with bases c.453+151 to c.453+166 (Fig. 5A ). The position of the secondary structure within the intron (Fig. 5B ) and the bases involved (Fig. 5C ) are shown. We will refer to bases c.454-323_-308 as long-distance interaction site 3 ′ (LDIS-3 ′ ) and to c.453+151_+166 as long-distance interaction site 5 ′ (LDIS-5 ′ ). The mfold data led to the hypothesis that formation of a double-stranded intra-intronic RNA structure between LDIS-5 ′ and LDIS-3 ′ functions to promote PLP1 splicing and mutations that reduce the stability of the predicted secondary structure would lead to reductions in the PLP1/DM20 ratio. We first tested constructs in which LDIS-5 ′ bases were mutated to the corresponding bases in LDIS-3 ′ . We also tested the reciprocal constructs in which bases in LDIS-3 ′ were mutated to corresponding bases in LDIS-5 ′ . In these constructs, base-pairing could not occur between identical bases so the double-stranded RNA structure would not be formed, and we predicted that the PLP1/DM20 ratio would be reduced. Further, we tested mutations in which we swapped bases between the two regions. In these constructs, base-pairing would occur, and we predicted that the normal PLP1/DM20 ratio would be reestablished.
When we mutated bases in LDIS-5 ′ so that base-pairing with LDIS-3 ′ would be disrupted, three of the four constructs (+153_+157AAGAA.TTCTT, +162_+165GTGC. CACG and +156_+157AA.TT) functioned as predicted by our hypothesis, reducing the relative PLP1/DM20 ratio to no more than 0.20 (Fig. 5D, black bars) . The remaining construct, c.453+165C.G, had a PLP1/DM20 ratio reduced to 0.69 of normal. Since the mutation of c.454-322G (in family A), which is predicted to be the complement of the base at c.453+165C in the intra-intronic structure, had reduced the PLP1/DM20 ratio to 0.12 of normal, we expected a similar reduction in the ratio for the c.453+165C.G base switch. However, we found a plausible explanation for this unexpected result that fit with our hypothesis by further investigating the secondary structure as follows. Material, Fig. S2A ). The three LDIS-5 ′ mutation constructs, which had reduced PLP1/DM20 ratios (+153_+157AAG AA.TTCTT, +162_+165GTGC.CACG and +156_+ 157AA.TT) had increased initial delta G values averaging 211.6 kcal/mol (Supplementary Material, Table S1 ), indicating a less-stable intra-intronic RNA structure. Likewise, in the secondary structure most likely to form with the c.453+165C.G base change, the guanine base mutation does not participate in base-pairing; however, there is a shift in base-pairing so that the guanine at position c.454-322 now base-pairs with the cytosine at position c.453+166, so an adenine-uracil base-pair is added (Supplementary Material, Fig. S2B ). The resulting initial delta G of 216.4 kcal/mol is relatively closer to the initial delta G of 217.6 kcal/mol for the normal test sequence indicating a partially stable structure, which correlates well with the intermediate transfection result for the c.453+165C.G mutation, a PLP1/DM20 ratio of 0.69 of normal, further supporting our hypothesis.
When we separately mutated additional bases in LDIS-3 ′ so that base-pairing with the LDIS-5 ′ would be disrupted, all four constructs functioned as predicted, reducing the relative PLP1/ DM20 ratio to 0.12 of normal or less (Fig. 5D , white bars with thin outlines). Finally, when we made 'double mutants' by swapping complementary bases between LDIS-5 ′ and LDIS-3 ′ of the proposed RNA structure, which was predicted to recreate the secondary stem structure depicted in Figure 5C , the relative PLP1/DM20 ratio was restored to nearly normal levels (ranging from 0.68 to 1.08), as anticipated (Fig. 5D , white bars with thick outlines). Together, these data demonstrate a longdistance interaction between LDIS-5 ′ and LDIS-3 ′ and support our hypothesis that formation of the intra-intronic secondary structure between the two sites acts to facilitate PLP1 splicing.
We further reasoned that if LDIS-5 ′ and LDIS-3 ′ are functionally important for PLP1/DM20 alternative splicing, the sequences and secondary structure would be conserved across mammalian species because the alternative splice of PLP1/ DM20 exon 3 is found throughout the mammalian lineage. When we performed bioinformatics analysis of conservation of the sequences at LDIS-5 ′ across 25 mammalian species, we found that all 16 bases are identical in each of the 25 mammalian * * * P , 0.001; * * P , 0.01; * P , 0.05; n.s., no significant difference. (C) Diagram comparing the 10 bases removed in deletions 3 and 4. The PMD family mutation at base c.454-322 is boxed. Seven of 10 bases are the same in these two segments, so deletion 4 effectively brings these seven bases into the same position as normal relative to the bases at region 5.
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PLP1 genes examined (Fig. 6A) . The conservation of LDIS-3 ′ was also very high, with only two sites of variability among species, bases c.454-318 and c.454-309 (Fig. 6B) . As shown in Figure 5C , base c.454-318 is within the secondary structure, but not paired, so any base would be tolerated at this position. Base c.454-309 is a uracil in most species, but it is a cytosine in some. Our data showed that a cytosine at this position had no significant effect on the PLP1/DM20 ratio (Fig. 4B) . Thus, the base-pairing in all 25 species is nearly identical (Fig. 6C) .
Outside of the bases in LDIS-5 ′ and LDIS-3 ′ , the conservation falls off. When we performed bioinformatics analyses of the secondary structures formed by intron 3 sequences across the 25 mammalian species, we found the LDIS-5 ′ and LDIS-3 ′ basepairing structure in the computed foldings for all of them. It is in the third-most energetically favorable structure for humans, but in 13 of the 25 species it is found in the most energetically favorable structure. These data showing conservation of LDIS-5 ′ and LDIS-3 ′ sequences and secondary structure across mammalian species argue that the mechanism regulating the alternative splice of PLP1 is functionally conserved.
The strong evidence for the importance of the secondary structure in PLP1/DM20 alternative splicing prompted us to further examine some of the results in the experiments shown in Figures 3 and 4 by using mfold. The region 5 deletion in LDIS-3 ′ that had reduced the PLP1/DM20 ratio dramatically (Fig. 3B ) also had a higher-than-normal initial delta G value of 26.3 kcal/mol, due to removal of seven double bonds in the structure (Supplementary Material, Fig. S2C ). However, the deletion of region 4 in LDIS-3 ′ had failed to reduce the PLP1/ DM20 ratio despite containing base c.454-322 that caused reduction of the PLP1/DM20 ratio when mutated in family A. We previously hypothesized that the function of the sequence in region 4 may have been compensated by moving the similar sequence in region 3 next to region 5 (Fig. 3C) . Using mfold analysis, we saw that because of the similar sequence next to the deleted region, deletion of region 4 resulted in a predicted secondary structure with an initial delta G value of 215.7 kcal/mol, similar to the normal structure (Supplementary Material, Fig. S2A and D) and consistent with the relatively normal PLP1/DM20 splice ratio that was observed. The data suggest that the function of the secondary structure is retained in the region 4 deletion construct by moving the similar sequence in region 3 next to region 5, thus lending support to our hypothesis. Another mutation, c.-318_-317GA.TT (Fig. 4) , at first appears to disrupt an adenine-uracil base-pairing only, so it would not be expected to reduce the PLP1/DM20 ratio significantly. However, when we subjected the test sequence containing this mutation to mfold, we found a predicted addition of a guanine-uracil base-pair and removal of a guanine-cytosine base-pair, leading to an initial delta G of 214.9 kcal/mol (Supplementary Material, Fig. S2E ), consistent with the moderate reduction in the PLP1/ DM20 ratio to 0.69.
When we plotted initial delta G values predicted from mfold against log 10 of the PLP1/DM20 ratio for normal and mutant Table S1 were included in this analysis. Structures that had an initial delta G value more positive than 214 kcal/ mol consistently had PLP1/DM20 ratios below 0.25 of normal [log 10 (20.6)]. Additionally, this plot suggests that a threshold delta G value of 216.4 kcal/mol or lower indicates a construct with sufficient base-pairing interactions for formation of an RNA structure adequate for near-normal levels of PLP1/DM20 splicing. We used our model of PLP1 intron 3 secondary structure and the mfold program to predict which bases are essential for the formation of the intra-intronic structure and therefore which mutations would result in an altered PLP1/DM20 ratio. We individually substituted each base in the structure with all possible mutations and recorded the free energy values (data not shown). For example, a change of c.453+150A to G, U or C resulted in a delta G value of 217.5 kcal/mol in mfold and was predicted not to change the PLP1/DM20 ratio. However, the change of c.453+151G to another base increased the delta G value to an average of 214.1 kcal/mol and was predicted to be likely to reduce the PLP1/DM20 ratio. Only the central nonpairing bases c.453+158 and c.454-315 are unessential for the formation of the secondary structure (Supplementary Material,  Fig. S3B ). Any single base change at this location is predicted to be unlikely to alter the PLP1/DM20 ratio, and indeed, we found that c.453-315T.G had a PLP1/DM20 ratio at 0.90 of normal levels (Fig. 4B) . These data are consistent with our hypothesis that the formation of secondary structure in intron 3 is required for normal regulation of the PLP1/DM20 alternative splice.
DISCUSSION
Mutations that dysregulate PLP1/DM20 alternative splicing by changing invariant sequences at splice donor or splice acceptor sites have been relatively simple to classify as likely causative mutations for PMD (13-16,21) . Further, mutations in both ESEs and ISEs near the donor and acceptor sites are likely causative mutations for PMD by loss of binding of splicing factors to the mutant sequences (14, 15, 20, 23, (27) (28) (29) . Because of the importance of the PLP1/DM20 alternative splice to expression of the gene and its sensitivity to mutation, we postulated that regulation of PLP1/DM20 alternative splicing could be controlled by elements acting from a distance into intron 3 of PLP1 and that there could be PMD patient mutations in these elements that are not typically sequenced by molecular diagnostics laboratories, but that are responsible for pathogenicity in some of the patients in whom PLP1 mutations have not been found. In this work, we identified regulatory sequences throughout intron 3 and a strong regulatory region, LDIS-3 ′ , 70% of the way into the intron that affects the PLP1/DM20 ratio. Bioinformatics analysis suggested that this region was capable of participating in a secondary structure with a site 15% of the way into the intron, LDIS-5 ′ . In domain swap experiments, we demonstrated that mutations introduced into either strand of the double-stranded RNA helix disrupted the secondary structure and decreased the alternatively spliced ratio of PLP1 to DM20, while reciprocal mutations that would stabilize the double-stranded RNA secondary structure restored the PLP1 to DM20 ratio to normal levels. In addition, we sequenced intron 3 in its entirety in patients with clinical diagnoses of PMD and strong suggestion of X-linked inheritance, who had tested negative for PLP1 duplication and DNA sequence mutations in molecular diagnostics laboratories. We report patients in three families with mutations in LDIS-3 ′ deep within intron 3 that reduced the PLP1/DM20 ratio in transfection experiments. Our data show that LDIS-5 ′ and LDIS-3 ′ interact to regulate the PLP1/DM20 alternative splice and strongly suggest that the interaction between them is the formation of secondary structure within intron 3. As diagrammed in Figure 7 , the secondary structure between LDIS-5 ′ and LDIS-3 ′ favors the PLP1 form, while disruption of the secondary structure favors the DM20 form. Our data also show that the patient mutations can cause PMD by disrupting the interaction, most likely by disrupting secondary structure. Our findings advocate for molecular diagnostics laboratories to include intron 3 when sequencing PLP1 in PMD patients and further suggest that introns involved in alternative splicing of other disease genes should be checked when disease-causing mutations cannot be found in coding sequences.
Often, genes have multiple sites that are recognized by prediction programs as splice donor sites. According to the oriented scanning mechanism (36) , which is the preferred mechanism underlying splice donor site selection, the 5 ′ -most splice donor site is used most often because it is the first to be encountered by the splicing machinery. In this regard, the 5 ′ -most site of Human
the PLP1/DM20 pre-mRNA is DM20, and it seems to be the default splice site, as it is the site that is used in all places where PLP1 is expressed except for the adult CNS (e.g. the peripheral nervous system, heart and early in development of the CNS) (17, 37, 38) . When PLP1 expression is upregulated in the oligodendrocytes of the CNS during development, there is a switch to use of the PLP1 splice donor site 105 bases downstream of the DM20 site. Little is known about the mechanism governing that shift, which results in alternative splicing of PLP1 pre-mRNA. The previously described ESEs and ISEs in PLP1 may play a role. We performed bioinformatics analyses to determine further factor-binding sites in a region of intron 3 that affects the PLP1/DM20 ratio and compared the results with our transfection data, but we did not clearly identify functional factor-binding sites in the LDIS-3 ′ region (Supplementary Material, Table S1 ). However, it is well known that these bioinformatics prediction analyses can give false results, identifying sites that are actually not present and missing sites that are present. We did not try further to validate predicted sites, and we did not search for binding sites that could have been missed. Splicing factors may play a role in alternative splicing of PLP1 by binding the secondary structure or the singlestranded RNA and interacting with the splicing machinery at the PLP1 and/or DM20 splice site. Alternatively, the secondary structure may play a role in promoting the use of the PLP1 splice donor site by bringing it into proximity with the splice acceptor site at exon 4, with destabilization of this structure shifting splicing back toward the default DM20 site.
Although the interaction of splicing factors with regulatory sequences in RNA is currently thought to play a larger role in splicing regulation than secondary structure, there are several reports of regulation by secondary structure in the literature, and various mechanisms have been proposed (39, 40) . Stem-loop structures are predicted to play roles in alternative splicing of genes such as human growth hormone (GH1), survival of motor neuron 2 (SMN2), microtubule-associated protein tau (MAPT) and troponin T, type 2 (TNNT2) (41) (42) (43) (44) . In some cases, specific splicing factors are known to play a role by binding to the sequences involved in the structure. For example, in the case of MAPT, an RNA helicase has been demonstrated to interact with a stem-loop structure and induce splicing of tau exon 10 (45). In the case of cTNA, the splicing factors muscle-blind (MBNL1) and U2AF65 regulate alternative splicing by binding double-and single-stranded RNA, respectively (44) . In the ENAH gene, the secondary structure functions as a bridge that positions a distal RBFOX splicing factor binding site close to alternative exon 11a, increasing inclusion of the exon (46) . In other cases, secondary structures are found to overlap or be in close proximity to splice donor or acceptor sites, facilitating binding of splicing factors (34, 47) . In the case of Lepidoptera 14-3-3 zeta pre-mRNAs, inclusion of mutually exclusive exons is largely regulated by RNA structure but is adjusted by splicing factor recognition (48) . The mechanism by which the secondary structure in intron 3 of PLP1 regulates splicing is currently unknown. Further studies will be needed to determine whether the structure itself regulates the alternative splice or whether splicing factors that bind the structure or positions near the structure are involved. While there is a report of the importance of a long-distance interaction in regulation of alternative splicing of SMN2 that is involved in the genetic disease spinal muscular atrophy (49) , to our knowledge, our article is the first to report disease-causing mutations that dysregulate alternative splicing by disruption of a long-distance interaction within an intron, probably by destabilization of secondary structure.
MATERIALS AND METHODS

Preparation of minigene splicing constructs for transfection
An artificial minigene construct containing the PLP1 genomic sequences from base c.123 within exon 2 to c.468 of exon 4 inserted into the neomycin gene under control of the Rous sarcoma virus (RSV) promoter has been described (Fig. 1B ) (13) . Two bases in the original minigene construct that were found to differ from the reference sequence in intron 2 (at c.192-147A.G previously reported and at c.191+ 218_219insT) were corrected to match the reference genome sequence by site-directed mutagenesis using the QuikChange Multi Site-directed Mutagenesis Kit (Agilent Technologies, Inc., Santa Clara, CA, USA) with primers I2cor1 and I2cor2 (Supplementary Material, Table S2 ) according to the manufacturer's instructions (13) . Resulting plasmids were confirmed to be identical to the reference sequence (Z73964) by sequence analysis. The corrected minigene construct, designated pRSVneoPLP1-NRL, was mutated as described below. Six constructs containing overlapping 210-base deletions of intron 3 were created. A SalI site was positioned at the 5 ′ end of the regions targeted for deletion, and an XhoI site was placed at the 3 ′ end using QuikChange Multi Site-Directed mutagenesis and mutagenesis primers [Integrated DNA Technologies (IDT), Coralville, IA, USA] (Supplementary Material, Table S2 ). Each plasmid was digested with SalI and XhoI to remove an intron portion and re-ligated. The constructs were designed so that the natural donor, branch-point and acceptor sites were not modified. Additionally, six constructs were made in which a replacement sequence of 210 bases was used to replace the deleted sequence. The replacement was a randomly generated sequence, from which any potential exonic splicing enhancers (ESEs) or splice sites, identified by bioinformatics analysis, were removed (Supplementary Material, Table S3 ). The double-stranded replacement sequence was created by hybridizing 11 overlapping oligonucleotide primers (listed in Supplementary Material , Table S3 ), ligating, cloning into the pPCR-Script vector, then digesting with SalI and XhoI. The resulting SalI-XhoI fragment was ligated into each of the SalIXhoI-digested deletion constructs.
Constructs containing 10-base deletions, or substitutions of one to five bases within intron 3, were made with the QuikChange Lightning Site-Directed Mutagenesis Kit (Agilent Technologies, Inc.). The sequence of the forward mutagenic oligonucleotide primer (IDT and Eurofins MWG Operon, Huntsville, AL, USA) used to make each construct are indicated (10-base deletions, Supplementary Material, Table S4 ; 1-5-base substitutions, Supplementary Material, Table S5 ). The complementary primers used to make each construct are not shown.
Cell culture and transfections
Oli-neu cells were maintained in DMEM/N1/1% horse serum growth medium containing 2 mM L-glutamine (Invitrogen, Foster City, CA, USA), 10 mg/ml biotin (B4639, Sigma-Aldrich, St Louis, MO, USA), 2.5 mg/ml insulin (I5500, Sigma-Aldrich), 5 mg/ml apo-transferrin (T2036, Sigma-Aldrich), 100 mM putrescine dihydrochloride (P7505, Sigma-Aldrich), 20 mM progesterone (P0130, Sigma-Aldrich) and 0.03 mM sodium selenite (S5261, Sigma-Aldrich) on lysine-coated flasks (BD Biosciences, San Jose, CA, USA) (50) . Transfections of normal and mutant constructs into Oli-neu cells were performed in triplicate. Plasmid DNA was prepared using EndoFree Plasmid Maxi Kit (Qiagen, Valencia, CA, USA). Briefly, 0.6 × 10 6 cells were plated in each well of a lysine-coated six-well plate on day 1. On day 4, transfections were performed with plasmid DNA (0.5 mg) and Lipofectamine 2000 (Invitrogen) according to the manufacturer's protocol. On day 5, the medium was removed from the cells, and in-well lysis was performed. Adhering cells were dislodged with a rubber policeman and collected, and the resulting suspension was vortexed and stored or immediately processed for RNA isolation.
RNA isolation and reverse transcription-polymerase chain reaction (RT-PCR)
RNA was isolated from Oli-neu cells using the RNeasy Mini kit (Qiagen) and QiaShredders (Qiagen) according to the manufacturer's instructions for purification of total RNA from animal cells. Residual DNA was removed using Turbo DNA-free treatment (Life Technologies/Ambion, Austin, TX, USA). RNA was quantified with a NanoDrop ND-1000 spectrophotometer (Thermo Scientific, Waltham, MA, USA). The cDNAs were produced by first denaturing RNA at 658C for 5 min, then performing reverse transcription in a reaction mixture containing 300 ng of DNase-treated RNA, 4 U Omniscript Reverse Transcriptase (Qiagen), 1× Buffer RT (Qiagen), 0.5 mM each dNTP (Qiagen), 1 mM Oligo (dT) 15 primer (Promega, Madison, WI, USA) and 10 U rRNasin (Promega) which was incubated for 60 min at 378C.
PCR reactions were performed on the cDNA with Multiplex PCR kit (Qiagen) using 2 ml of the reverse transcription reaction in a 25 ml volume containing 0.2 mM of each primer, and 12.5 ml of Multiplex Master Mix (Qiagen). The reverse primer of each pair was labeled with 6-FAM. The reaction conditions were 15 min at 958C; 25 cycles of 30 s at 948C, 90 s at 608C and 90 s at 728C; and 10 min at 728C. Primers specific to the minigene construct, neo-ex2F/neo-ex4R (Supplementary Material, Table S6 ) (IDT and Eurofins MWG Operon), were designed to overlap the neo-exon2 and exon4-neo junctions (Fig. 1B) . These primers were then unable to amplify an endogenous neo-cassette in the Oli-neu cells or the endogenous mouse Plp1 (50). Amplification with primer pair neo-ex2F/neo-ex4R-6-FAM resulted in a 262 bp DM20 product and a 367 bp PLP1 product (including exon 3B). Dilutions of the multiplex ranging from 1:3 to 1:200 were subjected to capillary electrophoresis on a 3130xL Genetic Analyzer (Applied Biosystems, Foster City, CA, USA) along with a GS500 LIZ size standard. Data were analyzed using Peak Scanner Software v. 1.0 (Applied Biosystems). The ratio of PLP1 to DM20 was calculated by dividing the PLP1 signal by the DM20 signal resulting from the PCR with the neo-ex2F/neo-ex4R primers.
Human subjects and genetic testing
The study of human subjects was approved by the Institutional Review Board at Alfred I. duPont Hospital for Children, Table 1 summarizes the clinical presentations for patients with intron 3 mutations from families A, B, and C. Neurological examinations were performed by authors J.G. for family A, B.C. for family B and P.S. for family C. The clinical presentation in all three families is mild classical PMD. The PLP1 copy number change (duplication) and codingregion mutations, and GJC2 (formerly GJA12) mutations for families A and B were ruled out by diagnostic testing in the Molecular Diagnostics Laboratory at the Alfred I. duPont Hospital for Children and for family C in the DNA Laboratory of Child Neurology, 2nd School of Medicine, Charles University and University Hospital Motol, Prague. Linkage analysis for PLP1 was completed by PCR amplification of a microsatellite marker consisting of dinucleotide CA repeats in intron 1 with primers CA-PLP1 and CA-PLP2 (30) or CA-PLP4 (Supplementary Material, Table S6 ). Mutations in PLP1 were detected or confirmed by DNA sequence analysis in the Molecular Diagnostics Laboratory at the Alfred I. 
Skin fibroblast cultures
Skin fibroblast cultures were obtained by tissue explant as previously described (51) . RNA isolation and cDNA production from cultured skin fibroblasts was performed as described for Oli-neu cells earlier in this section. For analysis of PLP1 splicing in fibroblasts, the primer pairs were hGAPDH F/R (14), PLPF4/5R2 and PLPF3/5R2 (Supplementary Material, Table S6), with the reverse primer of each pair labeled with Cy5. Resulting PCR products (10 ml) were subjected to electrophoresis on a 4% NuSieve 3:1 agarose (Lonza, Basel, Switzerland) gel. The gels were imaged and quantified on a STORM imaging system using ImageQuant 5.2 software (Molecular Dynamics/GE Healthcare, Piscataway, NJ, USA). On the gels from the primer pair PLPF4/ 5R2-Cy5, the PLP1 and DM20 bands can be distinguished by size, and a heteroduplex band also results. Because one-half of this band is the DM20 product and one-half is the PLP1 product, one-half of the intensity value of this band is added to the intensity values for DM20 and PLP1 from this primer pair when determining the amounts relative to hGAPDH.
Bioinformatics analyses
In silico searches for cis-acting splicing elements were performed using RESCUE-ESE (http://genes.mit.edu/burgelab/ rescue-ese/, last accessed on 5 June 2014), ESEfinder 2.0 (http:// rulai.cshl.edu/tools/ESE2/, last accessed on 5 June 2014), ESEfinder 3.0 (http://rulai.cshl.edu/cgi-bin/tools/ESE3/esefinder. cgi?process=home, last accessed on 5 June 2014) and Automated Splice Site and Exon Definition Analysis (http://splice.uwo.ca/, last accessed on 5 June 2014) (2, (52) (53) (54) (55) . Donor and acceptor sites were investigated using Analyzer Splice Tool (http://ibis. tau.ac.il/ssat/SpliceSiteFrame.htm, last accessed on 5 June 2014) (56) . Analysis of the RNA structure within intron 3 from PLP1 genes of 25 mammalian species (Supplementary Material, Table S7 ) was investigated with the mfold web server (http:// mfold.rit.albany.edu/?q=mfold, last accessed on 5 June 2014) using default settings (35) . Note that while all mutations were described at the DNA level, predicted secondary structure was described at the RNA level, substituting uracil for thymidine.
Intron 3 sequences from the PLP1 genes across 25 mammalian species (Supplementary Material, Table S7 ) were formatted into FASTA with EMBOSS Seqret and compared using CLUSTAL W and CLUSTAL W PROF from SDSC Biology WorkBench (http://workbench.sdsc.edu, last accessed on 5 June 2014), and sequence logos were developed using WebLogo (http:// weblogo.berkeley.edu, last accessed on 5 June 2014) (57 -60) .
